Hematologic cancers captured center stage in the US review and approval news for the week, thanks to a new drug application for Incyte Corporation’s parsaclisib for three B-cell non-Hodgkin lymphoma indications and a supplemental filing for Novartis AG’s pioneering CAR-T therapy Kymriah in the most common of those three NHL cancers, follicular lymphoma.
Johnson & Johnson and Legend Biotech Corp. learned that their CAR-T candidate, ciltacabtagene autoleucel, would see a three-month...





